p53 as an Effector or Inhibitor of Therapy Response
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Although integrity of the p53 signaling pathway in a given tumor was expected to be a critical determinant of response to therapies, most clinical studies failed to link p53 status and treatment outcome. Here, we present two opposite situations: one in which p53 is an essential effector of cure by targeted leukemia therapies and another one in advanced breast cancers in which p53 inactivation is required for the clinical efficacy of dose-dense chemotherapy. If p53 promotes or blocks therapy response, therapies must be tailored on its status in individual tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044
PML is induced by oncogenic ras and promotes premature senescence
Ferbeyre, G., de Stanchina, E., Querido, E., Baptiste, N., Prives, C., & Lowe, S. W. (2000) · Genes & Development · doi:10.1101/gad.14.16.2015 · Cited by 536
Jackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintás-Cardama, A., Garza, D., Tavana, O., Yang, P., Manshouri, T., Li, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.027 · Cited by 329
Regulation of E2Fs and senescence by PML nuclear bodies
Vernier, M., Bourdeau, V., Gaumont-Leclerc, M.-F., Moiseeva, O., Bégin, V., Saad, F., Mes-Masson, A.-M., & Ferbeyre, G. (2011) · Genes & Development · doi:10.1101/gad.1975111 · Cited by 177
Bally, C., Adès, L., Renneville, A., Sebert, M., Eclache, V., Preudhomme, C., Mozziconacci, M.-J., de The, H., Lehmann-Che, J., & Fenaux, P. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.03.012 · Cited by 162
Self-citationThe Drug-Induced Degradation of Oncoproteins: An Unexpected Achilles' Heel of Cancer Cells?
Ablain, J., Nasr, R., Bazarbachi, A., & de Thé, H. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0087 · Cited by 44
Self-citation
Cited by
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Targeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84
“The absence of p53 in mouse models of this tumor results in a failure to cure this disease (Ablain et al. 2016).”
Background
Metadata
- Authors
- Ablain, J., Poirot, B., Esnault, C., Lehmann-Che, J., & de Thé, H.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2015-12-04
- Volume
- 6
- Issue
- 1
- Pages
- a026260
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2184712565
- Cited by
- 15
- References
- 7
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.